Loading
A phase 1/2 trial of DCC-3009 in gastrointestinal stromal tumour, run by Deciphera Pharmaceuticals, LLC, now recruiting.
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) is a phase 1/2 interventional study registered as NCT06630234 by Deciphera Pharmaceuticals, LLC, with 120 participants planned, started 2024-12-10 and due to reach its primary completion in 2028-05. Interventions recorded: DCC-3009.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares DCC, Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono), Gastrointestinal stromal tumour (GIST) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/